Stocks Health care NSRX
NYSE · Health careNasus Pharma Ltd (NSRX)
Nasus Pharma Ltd reported revenue of $1.2B in fiscal 2025. It posted a net loss of $5.9M. In fiscal 2025 capital spending exceeded operating cash flow by $4.9M. At December 31, 2025 it held $1.2M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 25, 2026.
Key facts about Nasus Pharma Ltd
- Net worth
- Nasus Pharma Ltd has a market value (market cap) of $34.1M at the latest share price, and shareholders' equity of $2.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.2B, with a net loss of $5.9M.
- Cash flow
- In fiscal 2025 operations used $4.9M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 25, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Nasus Pharma Ltd does
Nasus Pharma Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker NSRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.2B | -$5.9M | -$0.72 | -$4.9M |
| 2025 | n/a | -$1.5M | -$0.22 | n/a |
| 2023 | n/a | -$1.1M | -$0.20 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NSRX ranks in Health care
Latest SEC filings
What Nasus Pharma Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 14, 2026
- September 4, 2026
- September 1, 2026Form F-3 filing F-3
- August 19, 2026
- August 19, 2026Form POS AM filing POS AM
- August 17, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 28, 2026
- June 9, 2026
Insider trades
What the people running Nasus Pharma Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 17, 2026 | Teleman Dan BenjaminChief Executive Officer, Director | Bought | 6,550 | $20.3K |
| April 22, 2026 | Teleman Dan BenjaminChief Executive Officer, Director | Bought | 2,900 | $10.9K |
| March 31, 2026 | Teleman Dan BenjaminChief Executive Officer, Director | Bought | 15,000 | $30.6K |
Who owns NSRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Udi Gilboa13G, passive | 21.1% | November 10, 2025 |
| Dr. Dalia Megiddo13G, passive | 20.9% | November 12, 2025 |
| Dr. Ronnie Hershman13G, passive with 1 related filers | 15.3% | November 13, 2025 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 9.99% | August 14, 2026 |
| Capital Point Ltd.13G, passive | 6.35% | August 20, 2025 |
| Funicular Funds, LP13G, passive with 2 related filers | 5.2% | April 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 10 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Balyasny Asset Management L.P. | 898,473 | 0 |
| Cable Car Capital, LP | 616,081 | +14,083 |
| Velan Capital Investment Management LP | 359,390 | 0 |
| Hudson Bay Capital Management LP | 134,771 | 0 |
| Bleichroeder LP | 89,848 | 0 |
| Citadel Advisors LLC | 22,004 | new |
| XTX Topco Ltd | 16,640 | new |
| Renaissance Technologies LLC | 12,200 | new |
| Morgan Stanley | 1,000 | -1,000 |
| Caitong International Asset Management Co., Ltd | 4 | new |
Insiders
1 insiders reported holding 163,541 shares in total, about $475.9K at the last price.
| Holder | Shares |
|---|---|
| Teleman Dan BenjaminChief Executive Officer, Director | 163,541 |
Questions about NSRX
What does Nasus Pharma Ltd do?
Nasus Pharma Ltd is a company in the Health care sector, listed on NYSE as NSRX. Its shares trade on NYSE under the ticker NSRX.
What is Nasus Pharma Ltd's net worth?
Nasus Pharma Ltd has a market value (market cap) of $34.1M at the latest share price, and shareholders' equity of $2.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Nasus Pharma Ltd profitable?
No. In fiscal 2025 it reported a net loss of $5.9M on revenue of $1.2B.
How much revenue does Nasus Pharma Ltd make?
In fiscal 2025 Nasus Pharma Ltd reported revenue of $1.2B.
When did Nasus Pharma Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 25, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the new insider holdings from September 23, 2026.
Similar companies
Compare NSRX with
Follow NSRX
Get an email when Nasus Pharma Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Nasus Pharma Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.